Rethinking Treatment Goals in Psoriasis: Leveraging IL-17 Inhibitors to Move Beyond Skin Clearance Toward PsA Prevention - Episode 10
Evaluating the Safety Profile of IL-17 Inhibitors in Psoriatic Disease
In this episode, the panelists focus on evaluating the safety profile of IL-17 inhibitors in psoriatic disease. The experts explain that IL-17 therapies are generally well tolerated and offer a favorable safety profile compared with older systemic agents like TNF inhibitors and methotrexate, which require frequent lab monitoring. They note that while all IL-17 inhibitors share certain class effects, the most commonly observed adverse event is mucosal or oral candidiasis, which is typically mild, manageable, and tends to decrease over time. The panelists emphasize careful patient selection, avoiding IL-17 inhibitors in individuals with a history of inflammatory bowel disease (IBD), given the risk of exacerbation. They briefly discuss safety observations from dual IL-17A and IL-17F blockade, noting reports of liver enzyme elevation and mood changes, though these lack strong mechanistic evidence. Overall, the experts conclude that IL-17 inhibitors provide a safe, targeted, and effective option for long-term psoriasis and PsA management.
In this episode, the panelists focus on evaluating the safety profile of IL-17 inhibitors in psoriatic disease. The experts explain that IL-17 therapies are generally well tolerated and offer a favorable safety profile compared with older systemic agents like TNF inhibitors and methotrexate, which require frequent lab monitoring. They note that while all IL-17 inhibitors share certain class effects, the most commonly observed adverse event is mucosal or oral candidiasis, which is typically mild, manageable, and tends to decrease over time. The panelists emphasize careful patient selection, avoiding IL-17 inhibitors in individuals with a history of inflammatory bowel disease (IBD), given the risk of exacerbation. They briefly discuss safety observations from dual IL-17A and IL-17F blockade, noting reports of liver enzyme elevation and mood changes, though these lack strong mechanistic evidence. Overall, the experts conclude that IL-17 inhibitors provide a safe, targeted, and effective option for long-term psoriasis and PsA management.
